

TW
Box Seg

G-10 Inc.

P.O. Box 223662
Chantilly, VA 20154
Ph. (703) 542-5588
Cell (703) 725-9876



Date: November 1, 2006

Dr. Ronald Schwadron, Ph.D
Art unit 1644
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313, 1450

Re: Application No 09/474 677 D
Applicant : Yash Sharma

Dear Dr. Schwadron:

This has reference to my interview with you on October 18, 2006 in your office regarding sequence listing. Thanks for your advice and help. Please find the enclosed corrected sequence listing, and also the NIH web page listing Lukor as anti-HIV compound and USDA table listing NGNA as component of common food items. Also included in this package is our human clinical trials using NGNA derived from common food item Sea cucumber and related references.

These documents provide sufficient evidence of enablement and further proof of NGNA as potential natural anti - HIV compound.

In view of these evidences, the application is in good condition for allowance.

Respectfully submitted.

Yash
Yash Sharma, Ph.D
43393 Cedar Pond Place
CHANTILLY VA 20152



Notice to Comply	Application No 09/474677	Applicant(s)	
	Examiner Ron Schwadron, Ph.D.	Art Unit 1644	
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES			
<p>Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).</p> <p>The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):</p>			
<p><input checked="" type="checkbox"/> 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).</p> <p><input type="checkbox"/> 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).</p> <p><input type="checkbox"/> 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).</p> <p><input checked="" type="checkbox"/> 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."</p> <p><input type="checkbox"/> 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).</p> <p><input type="checkbox"/> 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).</p> <p><input type="checkbox"/> 7. Other:</p>			
<p>Applicant Must Provide:</p> <p><input checked="" type="checkbox"/> An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".</p> <p><input checked="" type="checkbox"/> An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application.</p> <p><input checked="" type="checkbox"/> A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).</p>			
<p>PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY</p>			